
June 25 (Reuters) - Assembly Biosciences Inc ASMB.O:
ASSEMBLY BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1B CLINICAL TRIAL OF NEXT-GENERATION INVESTIGATIONAL CAPSID ASSEMBLY MODULATOR ABI-4334 IN CHRONIC HEPATITIS B
ASSEMBLY BIOSCIENCES INC - ABI-4334 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE